Tuesday, August 16, 2022

17 Aug 2022 BMD


 LOCAL MARKET


*~Let's Meet UP~*

Join Us For A Zoom Workshop, 'Futures Leading the Way (Chinese Session) 期货交易, 势在必得' 

17th August 2022 (Wednesday) 8pm - 9pm

Please Register Here: https://forms.gle/v1z6gGv4Udce2hAt5




If you like what we are doing, kindly like and share our page on FB. Follow us on FB for more updates.

Click here to contact us: https://goo.gl/B6Dccf 




FKLI

FKLI ended higher on late buying in selected index-linked telecommunication companies, amid mixed performance on the regional markets.

To subscribe to a real-time signal, email us at futures.coin@gmail.com for details. Sign up today for your Aug subscription.


Plan A : Consider long if the market stays above 1514. Targets are 1526 and 1533.

Plan B : Attempt short if the market stays below 1512. Targets are 1507 and 1502




FCPO

FCPO consolidates around the range of 4100 to 4300. Dalian closed -4 at 8628 while soybean oil traded +0.62 at 66.68. Ringgit weakened to 4.46 against the greenback.

To subscribe to a real-time signal, email us at futures.coin@gmail.com for details. Sign up today for your Aug subscription.


Plan A : Long only if market rebound and supported firm above 4245. Targets are 4285 and 4310.

Plan B : Short if market rebounded but failed to support above 4245. Targets are 4212 and 4196.




Disclaimer: This information is intended to assist professional investors. News are credit courtesy of Reuters, Nasdaq.com, Bloomberg, CNN, Market Watch, FT.com, the Star online, forbes.com, mining.com and CNBC. The information does not constitute investment advice or an offer to invest or to provide management services and is subject to correction, completion and amendment without notice.As with all investments, there are associated risks and you could lose money investing. Prior to making any investment, a prospective investor should consult with its own investment, accounting, legal and tax advisers to evaluate independently the risks, consequences and suitability of
that investment.  

0 comments:

Post a Comment